Liraglutide - Medication and Pregnancy KB

Liraglutide

Exposed non-exposed studies (cohort)

Study	Country Study period	Population source	Exposure definition	Non-exposure definition	Sample size	Rmk
Broe (Controls unexposed, general pop), 2025	Denmark 2004 - 2017	All singleton livebirths in Denmark between January 1, 2004, and December 31, 2017.	Singleton livebirths whose mothers had filled a prescription for Liraglutide between the first day in the last menstrual period (LMP) and the end of the first trimester (91days after LMP).	unexposed (general population or NOS) Singleton livebirths of women who did not redeem any drug prescription between 90 days prior to LMP and the end of the first trimester.	55 / 482980	Infants with chromosomal abnormalities (ICD-10 codes Q90– Q99) were excluded from all analyses.
Broe (Controls unexposed, sick), 2025	Denmark 2004 - 2017	All singleton livebirths in Denmark between January 1, 2004, and December 31, 2017.	Singleton livebirths whose mothers had filled a prescription for Liraglutide between the first day in the last menstrual period (LMP) and the end of the first trimester (91days after LMP).	unexposed, sick Singleton livebirths born to women who were treated with the individual drug of interest during the last year before pregnancy, but not during pregnancy.	55 / 53	Infants with chromosomal abnormalities (ICD-10 codes Q90– Q99) were excluded from all analyses.
Maya, 2025	USA 2016 - 2025	Singleton pregnancies with delivery dates between June 1, 2016, and March 31, 2025, at Mass General Brigham, an academic health system with 15 institutions serving the greater Boston area in Massachusetts.	Singleton pregnancies with Liraglutide order in the electronic health record (EHR) between 3 years before and 90 days after conception.	unexposed (general population or NOS) Singleton pregnancies without Glucagon-like peptide-1 receptor agonist (GLP-1RA) medications recorded between 3 years before pregnancy and 90 days after conception.	145 / 435
Westergaard, 2025	Denmark 2009 - 2023	Pregnancies from October 2009 until December 2023.	Pregnancies with periconceptional Liraglutide exposure, was as the redemption of a liraglutide or semaglutide prescription (plus or less eight weeks from the calculated date of first date of the last menstruation).	unexposed (general population or NOS) Unexposed propensity score-matched pregnancies.	-9 / -9	Authors provided results for Liraglutide and Semaglutide and for 2 indications (pre-existing diabetes and weight management) => In the class meta-analysis, only 1 result was kept: the most precise: Liraglutide all indications.

Case-control studies (cohort)

Study	Country Study period	Case	Control	Sample size	Rmk

Warning! There are no case-control studies available for this drug.

master protocol